Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P757: Long-term effectiveness and safety of adalimumab based on Crohn’s disease duration: Results from the PYRAMID registryECCO '18 Vienna
Year: 2018
Authors:

E.V. Loftus Jr.1*, W. Reinisch2, R. Panaccione3, S. Berg4, M. Bereswill5, J. Kalabic5, M. Skup6, J. Petersson6, A.M. Robinson6, G. D'Haens7

1Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA, 2Medical University of Vienna, Vienna, Austria, 3University of Calgary, Calgary, Canada, 4AbbVie AB, Solna, Sweden, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6AbbVie Inc., North Chicago, USA, 7Academic Medical Center, Amsterdam, The Netherlands

P758: Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn’s disease (SVEAH CD)ECCO '18 Vienna
Year: 2018
Authors:

C. Eriksson1, S. Rundquist1*, V. Lykiardopoulos2, P. Karlén3, O. Grip4, C. Söderman5, S. Almer6, E. Hertervig7, J. Gunnarsson8, C. Malmgren9, J. Delin10, H. Strid11, M. Sjöberg12, D. Öberg13, D. Bergemalm1, R. Udumyan14, H. Hjortswang2, The SWIBREG SVEAH Study Group, J. Halfvarson1

1Faculty of Medicine and Health, Örebro University, Department of Gastroenterology, Örebro, Sweden, 2Linköping University, Department of Gastroenterology, Linköping, Sweden, 3Danderyd Hospital, Department of Internal Medicine, Stockholm, Sweden, 4Skåne University Hospital, Department of Gastroenterology, Malmö, Sweden, 5St Göran Hospital, Department of Internal Medicine, Stockholm, Sweden, 6Karolinska Institute, Department of Medicine, Stockholm, Sweden, 7Skåne University Hospital, Department of Gastroenterology, Lund, Sweden, 8Kungsbacka Hospital, Department of Internal Medicine, Kungsbacka, Sweden, 9Takeda Pharma AB, Solna, Sweden, 10Ersta Hospital, Department of Gastroenterology, Stockholm, Sweden, 11Södra Älvsborgs Hospital, Department of Internal Medicine, Borås, Sweden, 12Skaraborgs Hospital, Department of Internal Medicine, Lidköping, Sweden, 13Sunderby Hospital, Department of Internal Medicine, Sunderbyn, Sweden, 14Örebro University, Clinical Epidemiology and Biostatistics, Örebro, Sweden

P759: Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

T. Ochsenkühn1,2*, S. Janelidze2, C. Tillack2,3, F. Beigel3

1Isarklinikum, Gastroenterology, Munich, Germany, 2Synesis, IBD research center, Munich, Germany, 3University of Munich, Gastroenterology, Munich, Germany

P760: Monitoring of laboratory parameters during thiopurine maintenance therapy in patients with inflammatory bowel disease: An unnecessary burden?ECCO '18 Vienna
Year: 2018
Authors:

J.E. Kreijne1*, A.C. de Vries1, G. Bouma2, G. Dijkstra3, M.D. Voskuil3, R.L. West4, A.A. van Bodegraven5, D.J. de Jong6, N.K. de Boer2, C.J. van der Woude1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2VU University Medical Centre, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3University Medical Center Groningen and University of Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 4Franciscus Hospital and Vlietland Hospital, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 5Zuyderland Medical Center, Clinical Gastroenterology and Hepatology, Heerlen-Sittard-Geleen, The Netherlands, 6Radboud University Nijmegen Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands

P761: IFX dose-escalation strategy based on a population PK model in IBD patients with secondary loss of responseECCO '18 Vienna
Year: 2018
Authors:

J. Guardiola1*, L. Rodriguez Alonso1, K. Serra1, E. Santacana2, H. Colom3, F. Rodríguez-Moranta1, P. Gilabert1, C. Arajol1, E. Sanchez Pastor1, J. Bas4, A. Padullés2, N. Padullés2

1Hospital Universitario de Bellvitge, Gastroenterology, L´Hospitalet de Llobregat, Spain, 2Hospital Universitario de Bellvitge, Pharmacy, L´Hospitalet de LLobregat, Spain, 3Universitat de Barcelona, Pharmacy and pharmaceutical technology, Barcelona, Spain, 4Hospital Universitario de Bellvitge, Immunology, L´Hospitalet de LLobregat, Spain

P762: GO-CARE: A prospective multi-centre observational study of golimumab effectiveness and quality of life in a real-life UC patient population in ItalyECCO '18 Vienna
Year: 2018
Authors:

A. Armuzzi1*, S. Marchi2, A. Gasbarrini3, S. Saibeni4, A. Geccherle5, M. Principi6, V. Germano7, F. Bossa8, A.C. Privitera9

1IBD Unit, Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, 2Division of Gastroenterology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, 3Internal Medicine, Gastroenterology and Liver Unit, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy, 4Gastroenterology Unit, RhoHospital, Rho, Italy, 5Intestinal Bowel Disease Unit,Ospedale Sacro Cuore Don Calabria, Negrar Verona, Italy, 6Gastroenterology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, 7MSD, Roma, Italy, 8Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo Foggia, Italy, 9IBD and Pelvic Floor Unit, Azienda ospedaliera per l'emergenza, Ospedale Cannizzaro, Catania, Italy

P763: Quality of life in Paediatric inflammatory bowel disease Patient: How well do we understand patients?ECCO '18 Vienna
Year: 2018
Authors:

S. Kim, S. Park, Y. Kang, H. Koh

Severance Children's Hospital, Department of Pediatrics, Seoul, South Korea

P764: Drug level thresholds in patients with Crohn’s disease on dose-intensified anti-TNF therapy predict intestinal wall healing for infliximab but not adalimumabECCO '18 Vienna
Year: 2018
Authors:

R. Little*, H. Su, A. Friedman, S. Williams, P. Gibson, M. Ward, K. Taylor, M. Sparrow

Alfred Health and Monash University, Gastroenterology, Melbourne, Australia

P765: Role of C-reactive protein kinetics after surgery for Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Carvello*, F. Di Candido, G. Fiorino, S. Danese, A. Spinelli

Humanitas Research Hospital, Rozzano, Milan, Italy

P766: Quantum Blue® fCAL extended POC user performance evaluationECCO '18 Vienna
Year: 2018
Authors:

B. Fellay1, M. Drzewicka2, E. Burri3, M.-E. Ueberschlag4, A. Ritz4, J. Wieland4, M. Schneider4*

1Hôpital Cantonal Fribourg, Fribourg, Switzerland, 2Szpital Pediatryczny w Bielsku-Białej, Bielsko-Biała, Poland, 3Kantonsspital Baselland, Liestal, Switzerland, 4BÜHLMANN Laboratories AG, Schoenenbuch, Switzerland

P767: Quantum Blue® infliximab POC user performance evaluationECCO '18 Vienna
Year: 2018
Authors:

B. Fellay1, M. Kopertowska-Majchrzak2, E. Burri3, M.-E. Ueberschlag4, A. Ritz4, T. Schuster4*

1Hôpital Cantonal Fribourg, Fribourg, Switzerland, 2Wielospecjalistyczny Szpital Wojewódzki, Gorzów Wlkp, Poland, 3Kantonsspital Baselland, Liestal, Switzerland, 4BÜHLMANN Laboratories AG, Schoenenbuch, Switzerland

P768: Extended enoxaparin venous thromboembolism prophylaxis after surgery for inflammatory bowel disease: A cost-based decision-analysisECCO '18 Vienna
Year: 2018
Authors:

S. Holubar1*, P. Dulai2, B. Piazik3, S. Finlayson4, B. Udeh5

1Cleveland Clinic, Department of Colon and Rectal Surgery, Cleveland, USA, 2University of California San Diego, Medicine, San Diego, USA, 3Elliot Health Systems, Manchester, USA, 4University of Utah, Surgery, Salt Lake City, USA, 5Cleveland Clinic, Clinical Transformation, Cleveland, USA

P769: Hypophosphatemia in patients with inflammatory bowel disease after intravenous iron infusion: One centre prospective studyECCO '18 Vienna
Year: 2018
Authors:

E. Tulewicz-Marti1*, A. Moniuszko1, T. Korcz1, G. Rydzewska1,2

1Clinical Hospital of Ministry of Interior Affairs and Administration, Department of General Medicine and Gastroenterology with Inflammatory Bowel Disease Subdivision, Warsaw, Poland, 2Jan Kochanowski University, Faculty of Medicine and Health Science, Kielce, Poland

P770: Can we predict mucosal inflammation in children with inflammatory bowel disease without colonoscopy?ECCO '18 Vienna
Year: 2018
Authors:

M. Meglicka*, M. Szczepanski, M. Dadalski, J. Kierkus

The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P771: Diagnostic performance of low haemoglobin density (LHD%) for detecting iron deficiency in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

K. Farrag1,2*, K. Ademaj1,2, E. Leventi1,2, A. Aksan2,3, J. Stein1,2

1DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 2Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 3Hacettepe University, Faculty of Health Sciences, Ankara, Turkey

P772: Factors influencing adherence to oral 5-aminosalicylic acid in patients with ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

S.M. Lee1*, T.O. Kim2, J. Lee2, H.W. Kim3, S.R. Ji4

1Dongnam Institute of Radiological and Medical Sciences, Department of Internal Medicine, Busan, South Korea, 2Inje University Haeundae Paik Hospital, Department of Internal Medicine, Busan, South Korea, 3Pusan National University Yangsan Hospital, Department of Gastroenterology, Busan, South Korea, 4Inje University Busan Paik Hospital, Department of Internal Medicine, Busan, South Korea

P773: Rescue treatment with tacrolimus in patients with severe inflammatory bowel disease (IBD) without response to intensification of biological therapyECCO '18 Vienna
Year: 2018
Authors:

L. Sanchis*, X. Cortés, J. Clofent, J. Rodriguez, J.R. Molés, S. Fernández, J. Borrás

Hospital of Sagunto, Valencia, Spain

P774: Comparison of disease burden of ulcerative colitis patients treated with biologics/biosimilars in remission and not in remission across the EU5ECCO '18 Vienna
Year: 2018
Authors:

Y. Lu1*, A. Baskett2, H. Triggs2, B. Haven2, P. Collins2

1Ipsos Healthcare, Therapy Monitors, New York City, USA, 2Ipsos Healthcare, Therapy Monitors, London, UK

P775: Usefulness of endoscopic balloon dilation for colorectal strictures in patients with Crohn’s disease who underwent administration of TNF-α inhibitorECCO '18 Vienna
Year: 2018
Authors:

T. Takeda1*, F. Hirai1, S. Ishikawa2, Y. Yano2, K. Masahiro2, Y. Takada2, T. Beppu2, K. Yao3, T. Matsui2, T. Ueki2

1Fukuoka University Chikushi Hospital, IBD center, Chikushino-shi, Japan, 2Fukuoka University Chikushi Hospital, Gastroenterology, Chikushino-shi, Japan, 3Fukuoka University Chikushi Hospital, Endoscopy, Chikushino-shi, Japan

P776: Ferric carboxymaltose therapy in IBD patients with iron deficient anaemia: Real-life data from GermanyECCO '18 Vienna
Year: 2018
Authors:

J. Stein1,2*, S. Vollmer3, W. Klemm4, K. Nip5, S. Weber-Mangal5, A. Dignass1,6

1Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 2DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 3Gastroenterological practice, Göppingen, Germany, 4Gastroenterological practice, Cottbus, Germany, 5Vifor Pharma Deutschland GmbH, Munich, Germany, 6Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany